로딩 중…
지수 로딩 중…
Korro Bio, Inc.
KRRO· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$10.74+3.57%
2026-08-03
Financials
Valuation Metrics
Korro Bio, Inc.'s Market Cap is $155M. At end of 2025 it was $75M. Ranked #3054 of 3,112 in US market (top 98%), #1397 of 1,445 on NASDAQ (top 97%), #261 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 97%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $155M | US#3,054/3,112 Sec#261/269 |
| Revenue | $4M | US#2,947/3,112 Sec#193/269 |
| Net Income | $-113M | US—/3,112 Sec—/269 |
| Total Assets | $184M | US#2,992/3,112 Sec#252/269 |
| Net Assets | $120M | US#2,856/3,112 Sec#219/269 |
| Value | ||
| P/B | 1.29x | US#624/3,112 Sec#28/269 |
| P/S | 40.32x | US#2,867/3,112 Sec#163/269 |
| FCF Yield | -45.58% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -94.87% | US#2,847/3,112 Sec#218/269 |
| ROA | -61.81% | US#3,006/3,112 Sec#239/269 |
| Op. Margin | -2154.03% | US#2,935/3,112 Sec#182/269 |
| Revenue Growth | -100.00% | US#2,948/3,112 Sec#190/269 |
| Financial Health | ||
| Debt Ratio | 53.49% | US#611/3,112 Sec#142/269 |
| Total Debt | $43M | US#2,575/3,112 Sec#154/269 |
| FCF | $-71M | US#2,522/3,112 Sec#125/269 |
| Cash | $62M | US#2,491/3,112 Sec#216/269 |
| Current Ratio | 8.13x | US#302/3,112 Sec#97/269 |
| Performance | ||
| 1Y Return | -22.45% | US#2,765/3,112 Sec#225/269 |
| 1M Return | -23.29% | US#2,997/3,112 Sec#241/269 |
| From 52W High | -80.78% | US#3,089/3,112 Sec#266/269 |
| 1Y MDD | -89.72% | US#3,106/3,112 Sec#267/269 |
| Trading | ||
| Volume | 94,261 shares | US#2,957/3,112 Sec#264/269 |
| Trading Value | $998223.00 | US#3,027/3,112 Sec#258/269 |
| Per Share | ||
| EPS | $-12.48 | US—/3,112 Sec—/269 |
| BPS | $5.47 | US#2,184/3,112 Sec#126/269 |